

July 8, 2021

Tillman U. Gerngross, Ph.D.
Chief Executive Officer
Adagio Therapeutics, Inc.
303 Wyman Street, Suite 300
Waltham, MA 02451

Therapeutics, Inc.

Draft Registration Statement on Form S-1
2021

Re: Adagio

Amendment No. 1 to
Submitted June 28,
CIK No. 0001832038

Dear Dr. Gerngross:

We have reviewed your amended draft registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this letter by providing the requested information and either submitting an amended draft registration statement or publicly filing your registration statement on EDGAR. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing the information you provide in response to these comments and your amended draft registration statement or filed registration statement, we may have additional comments. Unless we note otherwise, our references to prior comments are to comments in our June 16, 2021 letter.

Amendment No. 1 to Draft Registration Statement
Prospectus Summary, page 1

1. comment 1 to the extent you continue to characterize ADG20 as having demonstrated an ability to "potently neutralize" SARS-CoV-2. We reissue prior comment 1 to the extent you continue to characterize ADG20 as having demonstrated an ability to "potently neutralize" SARS-CoV-2.
2. the extent that replacing "rapid" with "near term" on pages 4 and 5 did not provide the clarification we requested in our comment. We reissue comment 2 to the extent that replacing "rapid" with "near term" on pages 4 and 5 did not provide the clarification we requested in our comment.

Tillman U. Gerngross, Ph.D.
FirstName LastNameTillman U. Gerngross, Ph.D.
Adagio Therapeutics, Inc.
Company
July 8, 2021NameAdagio Therapeutics, Inc.
July 8,2 2021 Page 2
Page
FirstName LastName

You may contact Tara Harkins at (202) 551-3639 or Al Pavot at (202) 551-3738 if you have questions regarding the financial statements and related matters. Please contact Abby Adams at (202) 551-6902 or Irene Paik at (202) 551-6553 with any other questions.

Sciences

cc: Divakar Gupta